What does ML Pharma do?

ML Pharma is a pharmacy in Brussel. Private Limited, started on 2 January 2023, 1 establishment.

What is the address of ML Pharma?

The registered office of ML Pharma is located at Houba de Strooperlaan 773, 1020 Brussel.

Is ML Pharma still active?

Yes. According to the CBE (4 October 2026) ML Pharma is active, legal situation “Normale toestand”, started on 2 January 2023.

Is ML Pharma registered on Peppol?

Yes, ML Pharma is registered on the Peppol network with ID 0208:0795627454.

What is the enterprise number of ML Pharma?

The enterprise number of ML Pharma is BE0795627454.

When was ML Pharma founded?

ML Pharma was founded on 2 January 2023.

Who are the directors of ML Pharma?

According to the 2025 annual accounts, the directors of ML Pharma are: AMALE IGASS.

Is ML Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 January 2023; 3 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did ML Pharma make in 2025?

ML Pharma posted a profit after taxes of € 13,891 in financial year 2025.

What is the revenue of ML Pharma?

As a small company, ML Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 211,334.

How much does an employee at ML Pharma earn?

The average wage cost per full-time employee at ML Pharma was € 45,500 in 2025: staff costs of € 136,369 for 3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ML Pharma have?

According to the 2025 annual accounts, ML Pharma has 3 full-time equivalents (FTE).

ML Pharma (Private Limited) - Brussel - BE0795627454

Dossier ML Pharma, printed on 4 October 2026 from databakkes.be/en/0795627454/ml-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ML Pharma from Brussel, company number BE0795627454, closed financial year 2025 with a result of € 13,891 after tax. For that financial year ML Pharma recorded a gross margin of € 211,334 and equity of € 122,318. Compared with financial year 2024, the result moved from € 66,859 to € 13,891. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.

What it is worth Growing

€ 122,318

▲ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 13,891

▼ 79% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 100,675

▼ 26% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 833 paid out

6 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 136,369

▲ 51% vs 2024

€ 45,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 93,987

▼ 14% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 205,793

▼ 24% vs 2024

€ 73,937 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 159,150

▲ 13% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 36,927

▲ 78% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 180,487 Gross margin 2023: € 180,487 First fiscal year in the series	€ 239,806 Gross margin 2024: € 239,806 ▲ 33% vs 2023 (€ 180,487) Favourable step	€ 211,334 Gross margin 2025: € 211,334 ▼ 12% vs 2024 (€ 239,806) Unfavourable step	▼ 12%
Profit after taxes	€ 34,093 Profit after taxes 2023: € 34,093 First fiscal year in the series	€ 66,859 Profit after taxes 2024: € 66,859 ▲ 96% vs 2023 (€ 34,093) Favourable step	€ 13,891 Profit after taxes 2025: € 13,891 ▼ 79% vs 2024 (€ 66,859) Unfavourable step	▼ 79%
Equity	€ 43,260 Equity 2023: € 43,260 First fiscal year in the series	€ 109,260 Equity 2024: € 109,260 ▲ 153% vs 2023 (€ 43,260) Favourable step	€ 122,318 Equity 2025: € 122,318 ▲ 12% vs 2024 (€ 109,260) Favourable step	▲ 12%
Total debts	€ 564,077 Total debts 2023: € 564,077 First fiscal year in the series	€ 533,987 Total debts 2024: € 533,987 ▼ 5% vs 2023 (€ 564,077) Favourable step	€ 451,585 Total debts 2025: € 451,585 ▼ 15% vs 2024 (€ 533,987) Favourable step	▼ 15%
Cash	€ 97,149 Cash 2023: € 97,149 First fiscal year in the series	€ 135,409 Cash 2024: € 135,409 ▲ 39% vs 2023 (€ 97,149) Favourable step	€ 100,675 Cash 2025: € 100,675 ▼ 26% vs 2024 (€ 135,409) Unfavourable step	▼ 26%
Retained profit	€ 33,260 Retained profit 2023: € 33,260 First fiscal year in the series	€ 99,260 Retained profit 2024: € 99,260 ▲ 198% vs 2023 (€ 33,260) Favourable step	€ 112,318 Retained profit 2025: € 112,318 ▲ 13% vs 2024 (€ 99,260) Favourable step	▲ 13%
Dividend	€ 833 Dividend 2023: € 833 First fiscal year in the series	€ 859 Dividend 2024: € 859 ▲ 3% vs 2023 (€ 833) Unchanged	€ 833 Dividend 2025: € 833 ▼ 3% vs 2024 (€ 859) Unchanged	▼ 3%
Bank debt	€ 333,748 Bank debt 2023: € 333,748 First fiscal year in the series	€ 271,248 Bank debt 2024: € 271,248 ▼ 19% vs 2023 (€ 333,748) Favourable step	€ 205,793 Bank debt 2025: € 205,793 ▼ 24% vs 2024 (€ 271,248) Favourable step	▼ 24%
Balance sheet total	€ 607,337 Balance sheet total 2023: € 607,337 First fiscal year in the series	€ 643,247 Balance sheet total 2024: € 643,247 ▲ 6% vs 2023 (€ 607,337) Unchanged	€ 573,903 Balance sheet total 2025: € 573,903 ▼ 11% vs 2024 (€ 643,247) Unchanged	▼ 11%
Employees (FTE)	2 Employees (FTE) 2023: 2 First fiscal year in the series	3 Employees (FTE) 2024: 3 ▲ 1 vs 2023 (2) Unchanged	3 Employees (FTE) 2025: 3 Unchanged (3) Unchanged

Key figures of ML Pharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ML Pharma?

What happened at ML Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 3, 2026 New annual accounts for financial year 2025: profit of € 13,891 (▼ 79% vs 2024). Source: NBB ↗
Jan 2, 2023 New establishment in Brussel. KBO
2023 AMALE IGASS became a director. NBB
Jan 2, 2023 Start of the company according to the CBE. KBO

In short

From € 34,093 profit in 2023 to € 13,891 profit in 2025.

Paid € 44,723 in corporate taxes since 2023.

Best year ever: 2024, with € 66,859 profit.

On average € 70,400 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at ML Pharma? We notify you, reason included.

Follow ML Pharma

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

AMALE IGASS

ML Pharma

Behind ML Pharma is AMALE IGASS.

See the full network in the app

Directors

According to the 2025 annual accounts

AMALE IGASS

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Houba de Strooperlaan 773

1020 Brussel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0795.627.454

VAT number

BE 0795.627.454

Registered office

Houba de Strooperlaan 773, 1020 Brussel

Names & denominations

ML Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 January 2023

Peppol

Active · Active since 18 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Detailhandel in cosmetica en toiletartikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

ML Pharma

Financials

What happened to ML Pharma?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions